

- 26 University, New York, NY
- 27 9. Department of Neuroscience, Mayo Clinic Florida, Jacksonville, Florida, USA
- 28 10. Department of Neurology and Penn Alzheimer's Disease Research Center, Perelman School of
- 29 Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- 30 11. Department of Pathology and Laboratory Medicine, School of Medicine, University of California
- 31 Davis, Sacramento, CA 95817, USA
- 32 12. Keck School of Medicine of the University of Southern California, Los Angeles, CA
- 33
- 34 ∗ **Contributed equally to this work.**

35 ∗ **Correspondence:**

- 36 Richard Mayeux, MD, MSc,
- 37 Chair of the Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia
- 38 University, and the New York Presbyterian Hospital, 630 West 168th street, New York, NY 10032,
- 39 USA; Tel: 212-305-2391; Email: rpm2@cumc.columbia.edu
- 40

41 Badri N. Vardarajan, Ph.D. MS

- 42 Assistant Professor of Neurological Science of the Department of Neurology, Vagelos College of
- 43 Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, 630 West
- 168th street, New York, NY 10032, USA; Tel: 212-342-5449; Email: **bnv2103@cumc.columbia.edu**
- 45

46 **Abstract: 334 words; Text: 2,918 words**

-
- 49
- 50
- 51

52 **Abstract**

53

54 **Background:**

55 Both genetic variants and epigenetic features contribute to the risk of Alzheimer's disease (AD). 56 We studied the AD association of CpG-related single nucleotide polymorphisms (CGS), which 57 act as the hub of both the genetic and epigenetic effects, in Hispanics decedents and generalized 58 the findings to Non-Hispanic Whites (NHW) decedents.

59

60 **Methods:**

61 First, we derived the dosage of the CpG site-creating allele of multiple CGSes in each 1 KB 62 window across the genome and we conducted a sliding window association test with clinical 63 diagnosis of AD in 7,155 Hispanics (3,194 cases and 3,961 controls) using generalized linear 64 mixed models with the adjustment of age, sex, population structure, genomic relationship matrix, 65 and genotyping batches. Next, using methylation and bulk RNA-sequencing data from the 66 dorsolateral pre-frontal cortex in 150 Hispanics brains, we tested the cis- and trans-effects of AD 67 associated CGS on brain DNA methylation to mRNA expression. For the genes with significant 68 cis- and trans-effects, we checked their enriched pathways.

69

70 **Results:**

- 71 We identified six genetic loci in Hispanics with CGS dosage associated with AD at genome-wide
- significance levels: *ADAM20* (Score=55.2, *P=*4.06x10-8 72), between *VRTN* (Score=-19.6,

P=1.47x10⁻⁸) and *SYNDIG1L* (Score=-37.7, *P*=2.25x10⁻⁹), *SPG7* (16q24.3) (Score=40.5,

- *P*=2.23x10⁻⁸), *PVRL2* (Score=125.86, *P*=1.64x10⁻⁹), *TOMM40* (Score=-18.58, *P*=4.61x10⁻⁸),
- 75 and *APOE* (Score=75.12, $P=7.26x10^{-26}$). CGSes in *PVRL2* and *APOE* were also genome-wide

93 **Introduction:**

115 Hispanics who enrolled Washington Heights-Inwood Columbia Aging Project (WHICAP) or the

254 $P=1.47x10^{-8}$) and *SYNDIG1L* (Score=-37.7, $P=2.25x10^{-9}$), *SPG7* (16q24.3) (Score=40.5,

272

273 **DNA methylation levels altering downstream cis-mRNA expression**: Next, we tested the 274 methylation sites cis-regulated by AD-associated CGSes (identified above), to determine 275 whether these sites altered downstream mRNA expression in the brain. Because our findings 276 revealed different methylation sites for the same gene in Hispanics and NHW for several AD 277 associated loci, we conducted an aggregate analysis by collapsing all the CpG sites within the

299 effects among individuals. Our study is one of the largest genome-wide association studies with

305

306 We identified six genome-wide significant windows in or near *ADAM20*, *VRTN*, *SYNDIG1L*, 307 *SPG7*, *PVRL2*, *TOMM40*, and *APOE*, where the dosage of the CpG dinucleotides (created by the

308 including CGSes) were associated with the risk of clinical diagnosis of AD. In *SPG7,* the AD

309 associated CGS window is associated with increased cis-DNA methylation levels in the frontal

310 cortex, which in turn reduced downstream mRNA expression. We validated the *SPG7* genetic

311 and epigenetic alterations in NHW, but there is no effect on mRNA expression. Similarly, for

312 *SYNDIG1L* and *APOE,* we identified AD-associated CGSes which in turn regulated methylation

313 levels in both Hispanics and NHW brains. However, but the epigenetic modifications had muted

314 effect on downstream gene expression. At *PVRL2*, both the cis effects and trans-effects were

315 statistically significant.

316

317 *SPG7* gene encodes paraplegin, a component of the m-AAA protease, an ATP-dependent 318 proteolytic complex of the mitochondrial inner membrane that degrades misfolded proteins and 319 regulates ribosome assembly. Our finding of its significant effects of its association with AD was 320 consistent with the previous report that the DNA methylation level at SPG7 was associated with 321 Braak neurofibraillary stages[18]. The *PVRL2* (a.k.a. *NECTIN2*) gene encodes a gene within the 322 nectin subfamily of immunoglobulin-like adhesion molecules that participate in Ca^{2+} -

336 does have limitations of potential bias by grey vs. white matter composition driven by different 337 protocol used by different sites. Also, the fact that multiple sites contribute to the brain samples 338 may also bring variations into the findings. Since the brain samples from different sites were 339 measured by different methylation batches, we only adjust for the experiment batches not the 340 sites in the regression model to remove the colinear bias.

341

342 This is the first report of robust six genetic loci covering seven genes that act as the hub for both 343 the genetic and epigenetic effects on clinical diagnosis of AD in Hispanic: *ADAM20*, between 344 *VRTN* and *SYNDIG1L*, *SPG7*, *PVRL2*, *TOMM40*, and *APOE*. *PVRL2* and *APOE* were also 345 genetically significant in NHW. Except *ADAM20*, all the other loci have significant mQTL

376 **Tables**

377 Table 1 Characteristics of donors of brain tissues

378 *The mean and standard deviation of the age at death are shown.
379 *The number and percentage of female are shown.

380

381

382 Table 2. Top CGS windows associated with Alzheimer's disease.

The dosage of CpG dinucleotides created by multiple CpG-related single nucleotide polymorphisms (CGSs) of each window were scaled into the value from 0 to

384 2, which was analyzed for its association with Alzheimer's disease using generalized linear mixed models (GLMMs) implemented in the generalized linear

385 mixed model association tests (GMMAT) with the adjustment of age, sex, and genotyping batches with the random effects of both kinship and genomic relationship matrix (GRM).

relationship matrix (GRM).

387

388

389

392 BETA, STDERR, and *P* represent the regression coefficient and its corresponding standard error, and P values of the generalized linear mixed regression model
393 where the dosage of CpG dinucleotides created by multip

393 where the dosage of CpG dinucleotides created by multiple CpG-related single nucleotide polymorphisms (CGSs) of each window were exposure variables and
394 DNA methylation level of each included CpG sites were outcome

394 DNA methylation level of each included CpG sites were outcome variable with the adjustment of age, sex, batches of genotyping and methylation, methylation array position with the random effect of methylation array.

395 array position with the random effect of methylation array.
396 Abbreviations: AD, Alzheimer's disease.

Abbreviations: AD, Alzheimer's disease.

397 *R* represent the correlation coefficient between two CpG sites.

398

399

401 Table 4. Cis-effects of DNA methylation on gene expression

402

403 #We have conducted a highly adaptive sum of powered score-weighted test to collapse all the available CpG sites within 100Kb distance to the gene and analyze

404 their associations on the gene expression and Braak stages. SPUw1 provides the direction of the score, indicating the effect direction of DNA methylation on gene expression, where aSPUw test simply combines the results

gene expression, where aSPUw test simply combines the results of multiple SPUw tests by taking the minimum *P* values. The model is gaussian for the

406 continuous gene expression values and the model is binomial for the binary variable of Braak stage, where score 5 and 6 are coded as 1 and scores from 1 to 4 are

407 coded as 0.

408 *T and *P* represent the statistic and its corresponding *P* values.

409 Abbreviations: SPUw1, sum of powered score-weighted 1 test; aSPUw, adaptive sum of powered score-weighted tests.

410

412 Table 5. Pathway analysis of the trans-effects of DNA methylation on gene expression.

414 **Figure 1. Manhattan plot of sliding window search across the genome for the risk loci of clinical diagnosis of Alzheimer disease.** Each dot 415 represents one 1-Kb window, and X and Y axis shows its genomic coordinate and -log10 transformed *P* value. The horizontal black line shows the 416 Bonferroni-corrected genome-wide significance threshold ($P \le 5 \times 10^{-8}$). The density of the windows across the genome were shown as color coded 417 bars with the color coding is shown on the right.

422 **References:**

423 1. Holstege H, Hulsman M, Charbonnier C, Grenier-Boley B, Quenez O, Grozeva D, et al. Exome 424 sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's 425 disease. Nat Genet. 2022;54(12):1786-94. Epub 2022/11/22. doi: 10.1038/s41588-022-01208-7. PubMed 426 PMID: 36411364; PubMed Central PMCID: PMCPMC9729101. 427 2. Nikolac Perkovic M, Videtic Paska A, Konjevod M, Kouter K, Svob Strac D, Nedic Erjavec G, et 428 al. Epigenetics of Alzheimer's Disease. Biomolecules. 2021;11(2). Epub 2021/02/13. doi: 429 10.3390/biom11020195. PubMed PMID: 33573255; PubMed Central PMCID: PMCPMC7911414. 430 3. Ma Y, Jun GR, Chung J, Zhang X, Kunkle BW, Naj AC, et al. CpG-related SNPs in the MS4A 431 region have a dose-dependent effect on risk of late-onset Alzheimer disease. Aging Cell. 432 2019;18(4):e12964. Epub 2019/05/31. doi: 10.1111/acel.12964. PubMed PMID: 31144443; PubMed 433 Central PMCID: PMCPMC6612647. 434 4. Shao Y, Shaw M, Todd K, Khrestian M, D'Aleo G, Barnard PJ, et al. DNA methylation of 435 TOMM40-APOE-APOC2 in Alzheimer's disease. J Hum Genet. 2018;63(4):459-71. Epub 2018/01/27. 436 doi: 10.1038/s10038-017-0393-8. PubMed PMID: 29371683; PubMed Central PMCID: 437 PMCPMC6466631. 438 5. Reyes-Dumeyer D, Faber K, Vardarajan B, Goate A, Renton A, Chao M, et al. The National 439 Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. 440 Alzheimers Dement. 2022;18(10):1889-97. Epub 2022/01/04. doi: 10.1002/alz.12514. PubMed PMID: 441 34978149; PubMed Central PMCID: PMCPMC9250549. 442 6. Gu Y, Honig LS, Kang MS, Bahl A, Sanchez D, Reyes-Dumeyer D, et al. Risk of Alzheimer's 443 disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington 444 Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP) cohort. Alzheimers Dement. 445 2024. Epub 2024/01/07. doi: 10.1002/alz.13652. PubMed PMID: 38183363. 446 7. Vardarajan BN, Faber KM, Bird TD, Bennett DA, Rosenberg R, Boeve BF, et al. Age-specific 447 incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: 448 National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell
449 Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia G Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en 450 Alzheimer (EFIGA). JAMA Neurol. 2014;71(3):315-23. Epub 2014/01/16. doi: 451 10.1001/jamaneurol.2013.5570. PubMed PMID: 24425039; PubMed Central PMCID: PMCPMC4000602. 452 8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of 453 Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of 454 Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-44. doi: 455 10.1212/wnl.34.7.939. PubMed PMID: 6610841. 456 9. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of 457 dementia. Br J Psychiatry. 1982;140:566-72. Epub 1982/06/01. doi: 10.1192/bjp.140.6.566. PubMed 458 PMID: 7104545. 459 10. De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al. A multi-omic atlas of the 460 human frontal cortex for aging and Alzheimer's disease research. Sci Data. 2018;5:180142. doi: 461 10.1038/sdata.2018.142. PubMed PMID: 30084846; PubMed Central PMCID: PMCPMC6080491. 462 11. Hinton L, Carter K, Reed BR, Beckett L, Lara E, DeCarli C, et al. Recruitment of a community-463 based cohort for research on diversity and risk of dementia. Alzheimer Dis Assoc Disord. 464 2010;24(3):234-41. Epub 2010/07/14. doi: 10.1097/WAD.0b013e3181c1ee01. PubMed PMID: 20625273; 465 PubMed Central PMCID: PMCPMC2946798. 466 12. Santos OA, Pedraza O, Lucas JA, Duara R, Greig-Custo MT, Hanna Al-Shaikh FS, et al. 467 Ethnoracial differences in Alzheimer's disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort. 468 Alzheimers Dement. 2019;15(5):635-43. Epub 2019/02/23. doi: 10.1016/j.jalz.2018.12.013. PubMed 469 PMID: 30792090; PubMed Central PMCID: PMCPMC6511501.

470 13. Heiss JA, Just AC. Improved filtering of DNA methylation microarray data by detection p values 471 and its impact on downstream analyses. Clin Epigenetics. 2019;11(1):15. doi: 10.1186/s13148-019-0615- 472 3. PubMed PMID: 30678737; PubMed Central PMCID: PMCPMC6346546.

- 473 14. Chen YA, Lemire M, Choufani S, Butcher DT, Grafodatskaya D, Zanke BW, et al. Discovery of
- 474 cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray.
- 475 Epigenetics. 2013;8(2):203-9. doi: 10.4161/epi.23470. PubMed PMID: 23314698; PubMed Central 476 PMCID: PMCPMC3592906.
- 477 15. McCartney DL, Walker RM, Morris SW, McIntosh AM, Porteous DJ, Evans KL. Identification
- 478 of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. 479 Genom Data. 2016;9:22-4. doi: 10.1016/j.gdata.2016.05.012. PubMed PMID: 27330998; PubMed Central
- 480 PMCID: PMCPMC4909830.
- 481 16. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of 482 Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45(4):e22. doi:
- 483 10.1093/nar/gkw967. PubMed PMID: 27924034; PubMed Central PMCID: PMCPMC5389466.
- 484 17. Chen H, Wang C, Conomos MP, Stilp AM, Li Z, Sofer T, et al. Control for Population Structure
- 485 and Relatedness for Binary Traits in Genetic Association Studies via Logistic Mixed Models. Am J Hum 486 Genet. 2016;98(4):653-66. doi: 10.1016/j.ajhg.2016.02.012. PubMed PMID: 27018471; PubMed Central
- 487 PMCID: PMCPMC4833218.
- 488 18. Li QS, Sun Y, Wang T. Epigenome-wide association study of Alzheimer's disease replicates 22 489 differentially methylated positions and 30 differentially methylated regions. Clin Epigenetics.
- 490 2020;12(1):149. Epub 2020/10/19. doi: 10.1186/s13148-020-00944-z. PubMed PMID: 33069246;
- 491 PubMed Central PMCID: PMCPMC7568396.
- 492 19. Tulloch J, Leong L, Thomson Z, Chen S, Lee EG, Keene CD, et al. Glia-specific APOE
- 493 epigenetic changes in the Alzheimer's disease brain. Brain Res. 2018;1698:179-86. Epub 2018/08/07. doi: 494 10.1016/j.brainres.2018.08.006. PubMed PMID: 30081037; PubMed Central PMCID: PMCPMC6388639.
- 495 20. Foraker J, Millard SP, Leong L, Thomson Z, Chen S, Keene CD, et al. The APOE Gene is
- 496 Differentially Methylated in Alzheimer's Disease. J Alzheimers Dis. 2015;48(3):745-55. Epub 2015/09/25.
- 497 doi: 10.3233/JAD-143060. PubMed PMID: 26402071; PubMed Central PMCID: PMCPMC6469491.
- 498 21. Lee EG, Tulloch J, Chen S, Leong L, Saxton AD, Kraemer B, et al. Redefining transcriptional 499 regulation of the APOE gene and its association with Alzheimer's disease. PLoS One.
- 500 2020;15(1):e0227667. Epub 2020/01/25. doi: 10.1371/journal.pone.0227667. PubMed PMID: 31978088; 501 PubMed Central PMCID: PMCPMC6980611.
- 502 22. Nguyen HD, Jo WH, Hoang NHM, Kim MS. In silico identification of the potential molecular mechanisms involved in protective effects of prolactin on motor and memory deficits induced by 1.2-
- mechanisms involved in protective effects of prolactin on motor and memory deficits induced by 1,2-
- 504 Diacetylbenzene in young and old rats. Neurotoxicology. 2022;93:45-59. Epub 2022/09/14. doi:
- 505 10.1016/j.neuro.2022.09.002. PubMed PMID: 36100143.
- 506

